Clinical Trial Update: Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tazemetostat in relapsed/refractory follicular lymphoma with EZH2 mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: Hutchmed | Conditions: Relapsed/Refractory Follicular Lymphoma With EZH2 | Phase 2 | Status: COMPLETED